1 Full title: Prevalence of carbapenem-resistant and extended-spectrum beta-

2 lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana.

3 Short title: carbapenem resistance in Enterobacteriaceae

- 4 James Sampah^{1,4}, Isaac Owusu-Frimpong^{1,2}, Frank T. Aboagye², Alex Owusu-Ofori^{1,3*}
- ⁵ ¹Department of Clinical Microbiology, School of Medicine and Dentistry, Kwame Nkrumah
- 6 University of Science and Technology, Kumasi, Ghana
- ⁷ ²Biomedical and Public Health Research Unit, CSIR-Water Research Institute, Accra, Ghana
- 8 ³Clinical Microbiology Unit, Laboratory Services Directorate Komfo Anokye Teaching
- 9 Hospital, Kumasi, Ghana
- 10 ⁴Laboratory Department, St. Patrick's Hospital, Offinso, Ghana
- 11 *Corresponding author: <u>ekowsampah@yahoo.com</u> (JS)

12 Abstract

Background: Carbapenem-resistant Enterobacteriaceae (CRE) and Extended-spectrum beta-13 lactamase (ESBL) production among Gram-negative Enterobacteriaceae is an increasing 14 global challenge because of the high morbidity and mortality associated with their infections, 15 especially in developing countries where there may not be many antibiotic treatment options. 16 . Despite these challenges, there are few studies in Ghana that have described the burden of 17 CRE. This study aimed to determine the prevalence of carbapenem-resistant 18 19 Enterobacteriaceae isolated from patients at the Cape Coast Teaching Hospital (CCTH) in the Central region of Ghana. 20

Methodology/Principal findings: Enterobacteriaceae isolates were collected from April to
 July 2019 at the bacteriology unit of CCTH using a consecutive sampling method. Isolates NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

were identified by standard microbiological techniques and confirmed using API 20E. Kirby 23 Bauer disc diffusion method was used to determine the antibiogram of isolates. Isolates were 24 also subjected to ESBL testing using the single-disc combination method. Carbapenem 25 resistant isolates were identified by the Kirby Bauer disc diffusion method and then subjected 26 to genetic confirmation using polymerase chain reaction (PCR). Of the 230 isolates 27 comprising E. coli (40.9%), Citrobacter spp. (32.6%), K. pneumoniae (9.1%), P. mirabilis 28 (6.1%), P. vulgaris (5.2%), Enterobacter spp (3.5%), K. oxytoca (2.2%), and Serratia 29 *marcenses* (0.4%). Majority of the isolates were from urine 162(70.4\%) and wound samples. 30 31 The isolates showed high resistance to ampicillin 171 (74.3%) and cefuroxime 134(58.3%). The prevalence of MDR was 35.2% (81) with E. coli 40(42.6%) being the majority that 32 exhibited MDR. Out of the 230 isolates, 113(49.1%) were ESBL producers with E. coli 33 54(57.5%) accounting for the majority while Serratia marcenses was the least. Out of the 13 34 (5.7%) CRE isolates which showed resistance towards carbapenem in the disc diffusion 35 method, 11 expressed the blaNDM-1 gene whilst all isolates which showed resistant CRE 36 expressed the blaOXA-48 gene. 37

38 Conclusion: The prevalence of carbapenem resistance and ESBL- producing
39 Enterobacteriaceae pathogens among patients at the CCTH, Cape coast of Ghana is high, and
40 effective infection prevention and control measures should be implemented at the hospital to
41 prevent the rapid spread of these dangerous organisms.

42 Keywords: Antibiotic resistance, extended-spectrum beta-lactamases, carbapenem
43 resistance, Enterobacteriaceae

44 Introduction

The occurrence of antimicrobial resistance (AMR) is a significant challenge in the treatment of infections and these infectious diseases are ever-increasing especially with the re-

emergence of pathogens [1]. AMR is considered to occur naturally and has been known to be escalated by the misuse and overuse of antimicrobial agents [2]. The increasing emergence of multidrug-resistant (MDR) Gram-negative bacilli is of great priority in clinical settings across the globe. Management of Gram-negative multidrug-resistant (MDR) infections has become significantly challenging over the past two decades in many developing countries, especially within the Sub-Saharan region [3]. These infections are usually associated with high morbidity rates, high mortalities, and extended hospital stays [4].

Enterobacteriaceae account for more than 30% of bacterial infections with high morbidity 54 55 and mortality outcomes [5, 6]. Meningitis, urinary tract infections, gastroenteritis, septicemia, pneumonia, and wound infections are just a few of the infections that these organisms 56 commonly cause [7, 8]. Enterobacteriaceae are well known for their public health threat 57 across the globe due to their increasing antimicrobial resistance. Studies have established that 58 59 members of this family of bacteria gain their antimicrobial resistance via the acquisition of drug-resistance genes through mobile genetic elements such as transposons and plasmids 60 61 transferred within the same species or different species [9, 10]. The acquired resistance genes facilitate the production of β -lactamase enzymes, especially the extended-spectrum β -62 lactamase (ESBL), responsible for conferring resistance to the majority of β -lactam 63 antibiotics [7, 10–13]. For instance, carbapenems, a class of β -lactam antibiotics, have been 64 established to lose their potency against Enterobacteriaceae due to resistance [7, 14]. Other 65 66 well-known antimicrobials such as fluoroquinolones, aminoglycosides. phenicols. sulfonamides, and tetracyclines have been rendered ineffective by this group of bacteria, 67 thereby making treatment of infections of these bacteria difficult [15–17]. 68

69 Carbapenems are broad-spectrum β -lactam antibiotics that are globally regarded as the 'last-70 line' antibiotics, thus, they are considered the last choice of drug for the treatment of 71 critically ill patients and/or those infected with resistant Gram-negative bacteria [18]. They

are essentially reserved for cases of suspected MDR bacterial infections. This class of β-72 lactam is very similar to penicillin and cephalosporin [19]. Carbapenems are bactericidal in 73 their mode of activity against bacterial species that are Gram-negative. Unlike other β-lactam 74 antibiotics, carbapenems invade the bacterial cell through the outer membrane proteins 75 (OprDs), other than those used by the cephalosporin and penicillin (OmpC and OmpF), 76 which results in the interruption of cell wall formation [18]. Once the cell wall formation is 77 78 interrupted by the carbapenems, the peptidoglycan layer becomes very weak and the cell eventually bursts leading to the death of the bacterial cell [20, 21]. 79

Generally, carbapenem-resistant Enterobacteriaceae (CRE) has been studied and reported in a 80 few African countries such as Tanzania, South Africa, Nigeria, Kenya, Morocco, and Ghana 81 [14, 22-36]. In Ghana, reported carbapenem resistance is not too different from other 82 developing and under-developed countries in Africa. In a study by Codjoe and colleagues 83 84 among Gram-negative isolates collected from four hospitals in Ghana, a 2.9% prevalence of carbapenem-resistant was reported [37]. The report further indicated that 23.4 % of the 85 bacterial isolates were harbouring known carbapenem-resistant genes; bla VIM-1, bla Oxa-86 48, and bla NDM-1. Another study conducted by Quansah and colleagues reported 87 carbapenem-resistant genes OXA- 48 (2.16%) and NDM-1 (0.72%) in the study population 88 89 [36].

While there are a few studies in other parts of Ghana that have looked at carbapenem
resistance in Enterobacteriaceae, there are no published data on CRE from the Central Region
of Ghana. As result, this study aimed to determine the prevalence of carbapenem-resistance,
MDR, and ESBL-producing Enterobacteriaceae in the Cape Coast Teaching Hospital, in the
Central Region of Ghana.

95 Materials and methods

96 Ethics statement

97 Cape Coast Teaching Hospital Ethical Review Committee (CCTHERC/EC/2019/044) of the 98 Cape Coast Teaching Hospital and Committee on Human Research, Publication and Ethics 99 (CHRPE/AP/201/19) of the School of Medical Sciences, Kwame Nkrumah University of 100 Science and Technology jointly approved the study. Informed consent was obtained from all 101 participants either by thumbprint or signature after an explanation of the procedure and the 102 purpose of the study was provided to the patient. Informed consent was obtained from parents 103 or guardians for participants below 18yrs.

104 Study setting

The study was conducted between April and October 2019, at Cape Coast Teaching Hospital 105 (CCTH) in Cape Coast in the Cape Coast Metropolitan, in the Central region of Ghana (Fig 106 1). The health facility is a tertiary government healthcare facility with a bed capacity of 420. 107 In 2018, the facility recorded out-patient attendance of 158,164 while the total admission was 108 10,865 [38]. During the period of sample collection (April to July 2019), the diagnostic 109 bacteriology unit received and processed 1,388 clinical specimens [38]. CCTH serves as a 110 referral hospital for the Central Region and other parts of the Western Region. The 111 metropolitan has a recorded population of 169,894, which comprises 82,810 (48.7%) males 112 and 87,084 (51.3%) females [39]. 113




Fig 1. The map of Ghana showing the location of Cape Coast Teaching Hospital in the 115 **Cape Coast Metropolitan District.** Map developed with ESRI ArcMap 10.8 using data from 116 Ghana Open Data Initiative, and OpenStreetMap and OpenStreetMap Foundation. 117

118

Bacterial collection 119

Two hundred and thirty (230) non-repetitive Enterobacteriaceae were isolated and identified 120 from the clinical specimens submitted using standard bacteriological techniques and a panel 121 of biochemical tests. Isolates were from urine, blood, sputum, high vaginal swab (HVS), 122 endocervical swab, wound swab, stools, and semen presented to the bacteriology unit at 123 CCTH. Using a pretested questionnaire, sociodemographic data including age and sex were 124 recorded. Isolates identification was confirmed using the API 20E strip (BioMerieux, 125 France). Isolates were maintained in 20% brain heart infusion glycerol broth at -20°C for 126 further testing. 127

128 Antibiotic susceptibility testing

All isolates from glycerol broth were subcultured on MacConkey agar media after partially 129 thawing the broth. Antibiotic susceptibility testing (AST) was performed on Mueller Hinton 130 agar using the Kirby Bauer disc diffusion method and interpreted according to the Clinical 131 and Laboratory Standards Institute (CLSI) guideline [40]. The AST was performed using 132 the following antibiotic discs; Ampicillin (10µg), Ciprofloxacin (5µg), Levofloxacin (5µg), 133 134 Ofloxacin (5µg), Gentamicin (10µg), Amikacin (30µg), Ceftriaxone (30µg), Ceftazidime (30µg), Cefotaxime (30µg) and Cefuroxime (30µg) which were from Biomark Laboratories, 135 136 India. Antibiotic discs Meropenem (10µg), Imipenem (10µg), and Ertapenem (10µg) from Oxoid, UK were included. E. coli (NCTC 19418) was used as a quality control strain. The 137 zones of inhibitions were recorded and interpreted according to the Clinical and Laboratories 138 Standards Institute guidelines [40]. Multidrug resistance was defined as resistance to at least 139 three classes of antibiotics [21]. 140

141 Phenotypic screening and confirmation for ESBL

ESBL detection was carried out on Mueller Hinton agar seeded with the test organism. All 142 230 isolates were screened for ESBL-producing enzymes using Ceftazidime (30µg) and 143 Cefotaxime (30µg) discs according to the method described by the CLSI guideline [40]. An 144 145 isolate resistant to any of the screening antibiotic discs was suspected of ESBL and reported as positive for ESBL screening. ESBL confirmation was done using a single disc of Oxoid 146 147 Cefpodoxime (10µg) alone and Cefpodoxime/ clavulanic acid (10/1µg) using the Kirby Bauer disc diffusion method [40]. The confirmatory discs were placed on the seeded Mueller 148 Hinton agar ensuring that the discs were at least 20mm apart and incubated at 37^oC overnight. 149 An enhanced zone of inhibition (≥ 5 mm) around the Cefpodoxime/ clavulanic acid (10/1µg) 150 151 relative to the single disc of Cefpodoxime (10µg) was considered positive for the production

of ESBL. *Escherichia Coli* ATCC 25299 and *K. pneumoniae* ATCC 700603 were used as
quality controls.

154 Molecular detection of carbapenem-resistant genes

After the antibiotic susceptibility testing using antibiotic discs, isolates that were resistant and intermediate susceptible to ertapenem, meropenem or imipenem were selected for genetic confirmation using polymerase chain reaction (PCR).

158 Bacterial DNA extraction

The DNA of bacteria isolates was extracted using Quick DNA kits (Zymo Research, USA) 159 according to the manufacturer's procedure. Using a sterile loop, a loopful of the isolates were 160 picked from the Mueller Hinton agar plate and emulsified in sterile 1.5 mL microcentrifuge 161 tubes containing 400 µL of Genomic Lysis Buffer and 5 µL Proteinase K. These tubes were 162 163 vortexed at 2500 rpm for 30sec and incubated at 56°C overnight. After the overnight incubation, mixtures were vortexed again and transferred to Zymo-Spin[™] IIC Columns in 164 165 collection tubes and centrifuged at 10,000 x g for one minute. The flow-throughs were discarded, after which 200 µL of DNA Pre-Wash Buffer was added to each spin column. 166 Centrifugation was performed again at 10,000 x g for one minute. Afterward, the final 167 washing was done by adding 500 µL of g-DNA Wash Buffer to the spin column and 168 centrifuging again at 10,000 x g for one minute. Finally, the spin columns were transferred 169 into sterile 1.5 mL microcentrifuge tubes, after which 100 µL of Elution Buffer was added to 170 elute the DNA. DNA samples were stored at -20°C before proceeding to downstream 171 analysis. DNA quantification was performed to determine the individual concentrations of the 172 isolate with the Qubit 3.0 fluorometer (Life Technologies Holdings Pte Ltd, Malaysia) and 173 the values recorded. 174

175 Detection of carbapenem resistance-encoding genes using PCR

Carbapenem-resistant isolates were examined for the presence of *blaKPC-1*, *blaIMP-1*, 176 *blaVIM-1*, *blaNDM-1*, and *blaOXA-48* genes by PCR methods using gene-specific primers 177 (Table 1) described by Poirel and colleagues [27]. The PCR assay was carried out with a 20 178 µL reaction mixture containing 2 µL genomic-DNA, 1x Standard reaction buffer, 0.3mM 179 each of dATP, dCTP, dTTP, and dGTP, 200 nM each of Forward and Reverse primers, and 180 181 1.25 U OneTaq DNA Polymerase (New England Biolabs Inc., USA). PCR reactions were performed using the Bio-Rad PTC-200 Thermal Cycler (Bio-Rad Laboratories, USA) with 182 183 the following cycling conditions; an initial denaturation at 94 °C for 3 mins, followed by 40 cycles at 94 °C for 30sec, 56 °C for 30sec, and 68 °C for 30sec. Finally, an elongation step 184 was performed at 68°C for 5 minutes. Afterward, the PCR products were resolved by agarose 185 gel electrophoresis and visualized under UV light using UVP Bio-Doc- It Imaging system -186 trans-illuminator (AnalytikJena, Germany). 187

188 Table 1. Carbapenem-resistant genes primer sets.

Gene	Sequence 5' → 3'	Fragment size (bp)
blaKPC-1	Forward: CGTCTAGTTCTGCTGTCTTG	798
	Reverse: CTTGTCATCCTTGTTAGGCG	
blaIMP-1	Forward: GGAATAGAGTGGCTTAAYTCTC	232
	Reverse: GGTTTAAYAAAACAACCACC	
blaVIM-1	Forward: GATGGTGTTTGGTCGCATA	390
	Reverse: CGAATGCGCAGCACCAG	
blaNDM-1	Forward: GGTTTGGCGATCTGGTTTTC	621
	Reverse : CGGAATGGCTCATCACGATC	
blaOXA-48	Forward: GCGTGGTTAAGGATGAACAC	438
	Reverse: CATCAAGTTCAACCCAACCG	

NB: KPC, *Klebsiella pneumoniae* carbapenemase; IMP, Imipenemase; VIM, Verona
integron-encoded metallo-β-lactamase; *NDM*, New Delhi metallo-β-lactamase, OXA-48,
oxacillinase-48.


192 Statistical analysis

- 193 Data were entered using Microsoft Excel 2019 and analyzed using GraphPad Prism version
- 194 8.0 (Graphpad Inc., La Jolla, CA, USA). A simple frequency was used to describe the study
- 195 population with the socio-demographic and other relevant variables.
- 196
- 197 **Results**

198 Distribution of clinical specimen

- 199 Out of the 1388 samples processed, 230 isolates were identified as Enterobacteriaceae; 162
- 200 (70.4%) isolates were from urine, 23 (10.0%) from wound swab, 22 (9.6%) from HVS, 15
- 201 (6.5%) from sputum, 4 (1.7%) from blood, 2 (0.8%) from endocervical swab, 1 (0.4%) from

202 other types of specimens (Fig 2).



203



205 Sociodemographic characteristics of the study population

The study enrolled 230 participants from whose clinical specimens *Enterobacteriaceae* were isolated. Out of the total participants, 196 (85.2%) were out-patients while 34 (14.8%) were on admission at various wards. Most participants were >70years 43 (18.7%) while the age group with the least number of participants was children <10yrs 8 (3.5%). One hundred and

sixty-six (166) females representing 72.2% participated in the study while 64 (27.8%) were

211 males (Table 2).

			Age gi	roup [Nu	imber of	particip	ants (N)]	
	<10	11-20	21-30	31-40	41-50	51-60	61-70	>70	Total (%)
Male	2	2	6	6	2	10	15	21	64 (27.8)
Female	6	12	35	28	20	22	21	22	166 (72.2)
Outpatient	3	12	32	33	20	26	33	37	196 (85.2)
In-patients	5	2	9	1	2	6	3	6	34 (14.8)

212 Table 2. Gender and age distribution among participants

213

214 Distribution of isolates/organism

Of the 230 isolates collected for this study, *Escherichia coli* was the most frequent pathogen
94 (40.9%), followed by *Citrobacter* spp. 75 (32.6%), *Klebsiella pneumoniae* 21 (9.1%), *Proteus vulgaris* 12 (5.2%), *Proteus mirabilis* 14 (6.1%), *Enterobacter* spp. 8 (3.5%) *Klebsiella oxytoca* 5 (2.2%) and *Serratia marcenses* 1 (0.4%) (Table 3).

	Point of Care				
Isolate	Outpatient [N]	In-patient [N]	Total [N] (%)		
E. coli	80	14	94 (40.9)		
Citrobacter spp.	66	9	75 (32.6)		
K. pneumoniae	19	2	21 (9.1)		
P. vulgaris	9	3	12 (5.2)		
P. mirabilis	8	6	14 (6.1)		
Enterobacter spp.	8	0	8 (3.5)		
K. oxytoca	5	0	5 (2.2)		
Serratia marcenses	1	0	1 (0.4)		
Frequency	196	34	230 (100)		


219 **Table 3: Distribution of isolates**

220 Antibiotics susceptibility pattern of Enterobacteriaceae


Out of the total of 13 antibiotics tested, susceptibility was highest to amikacin (AMK) 221 (97.8%). This was followed by meropenem (MEM), imipenem (IMI), and ertapenem (ERT) 222 with frequencies of 224 (97.4%), 224 (97.4%), and 204 (88.7%), respectively. The antibiotics 223 to which isolates were most resistant were ampicillin (AMP) (74.4%), cefuroxime (CXM) 224 (58.3%), and cefotaxime (CTX) (50.9%). Concerning the use of other antibiotics, isolates 225 226 were resistant to Ciprofloxacin (33.0%) and gentamicin (19.2%) (Table 4). Penicillin (74.3%) was the class of antibiotic to which isolates showed the most resistance whilst carbapenem 227 228 (3.6%) was the class of antibiotic to which isolates showed the least resistance (Fig 3).

229 Table 4: Antibiotic susceptibility profile of *Enterobacteriaceae*

Antibiotic	Susceptible <i>n</i> (%)	Intermediate <i>n</i> (%)	Resistant <i>n</i> (%)
Ampicillin	46 (20)	13 (5.7)	171 (74.3)
Gentamicin	156 (67.8)	30 (13.0)	44 (19.1)
Amikacin	225 (97.8)	3 (1.3)	2 (0.9)
Ciprofloxacin	141 (61.3)	13 (5.7)	76 (33.0)
Levofloxacin	158 (68.7)	12 (5.2)	60 (26.1)
Ofloxacin	145 (63)	13 (5.7)	72 (31.3)
Cefuroxime	80 (34.8)	16 (6.9)	134 (58.3)
Cefotaxime	104 (45.2)	9 (3.9)	115 (50.9)
Ceftazidime	106 (46.1)	9 (3.9)	115 (50.0)
Ceftriaxone	108 (47.0)	9 (3.9)	113 (49.1)
Ertapenem	204 (88.6)	13 (5.7)	13 (5.7)
Meropenem	224 (97.4)	0 (0.0)	6 (2.6)
Imipenem	224 (97.4)	0 (0.0)	6 (2.6)







233

234 MDR and Extended-Spectrum Beta-Lactamase (ESBL) producing organisms

Out of the 230 isolates collected, eighty-one (81) isolates exhibited multidrug resistance (35.2%) toward antibiotics used. Among isolates that exhibited MDR, *E. coli* (42.6%) was in the majority while *Serratia marcenses* was the least. Out of 230 isolates screened for ESBL production, 113 (49.1%) were ESBL producers while 117 (50.9%) were non-ESBL producers. Among the ESBL producers, *E. coli* (23.5%) was in the majority while *Serratia marcenses* (0.4%) was the least. ESBL producers were found among all the species of isolates collected. (Table 5).

242

243

244

Table 5: MDR and ESBL among isolates				
Bacterial isolates	Number of	MDR	ESBL	Non-ESBL
	isolates (n)	n (%)	n (%)	n (%)
E.coli	94	40 (42.6)	54 (57.5)	40 (42.6)
Citrobacter spp.	75	25 (33.3)	31 (41.3)	44 (58.7)
Klebsiella pneumoniae	21	5 (23.8)	10 (47.6)	11 (52.4)
Proteus mirabilis	14	4 (28.6)	7 (50.0)	7 (50.0)
Proteus vulgaris	12	3 (25.0)	4 (33.3)	8 (66.7)
Enterobacter spp.	8	2 (25.0)	3 (37.5)	5 (62.5)
Klebsiella oxytoca	5	1 (20.0)	3 (60)	2 (40.0)
Serratia marcenses	1	1 (100)	1 (100)	0 (0.0)

81 (35.2)

113 (49.1)

117 (50.9)

245

246

Frequency

Molecular detection of Carbapenem-resistant genes 247

230

Thirteen (13) isolates that showed resistance and 13 isolates that showed intermediate 248 249 resistance to carbapenem from the Kirby Bauer disc diffusion test were selected for PCR (Fig 4, A). None of the isolates selected for PCR expressed blaKPC-1, IMP-1, and VIM-1. 250 BlaOXA-48 and blaNDM-1 were detected among some of the Carbapenem-Resistant 251 Enterobacteriaceae (CRE) isolates (Fig 4, A). Out of the 13 resistant isolates, 11 expressed 252 the blaNDM-1 gene whilst all resistant CRE expressed the blaOXA-48 gene (Fig 4, D). Also, 253 254 9 out of the 13 resistant isolates expressed both blaOXA-48 and blaNDM-1 resistant genes. P. mirabilis (26.7%) was the Enterobacteriaceae which expressed more of the OXA-48 gene 255 whilst E. coli (3.2%) was the least among the isolates which expressed the OXA-48 gene (Fig. 256 257 4, B). Also, P. mirabilis (20.0%) expressed more of the NDM-1 gene whilst E. coli (1.1%) was the isolate with the least expression of the NDM-1 gene (Fig 4, B). The 13 resistant 258 isolates with carbapenem-resistant genes detected were found among both outpatients 259 260 (53.8%) and in-patients (46.2%). The blaOXA-48 gene was also found among all 13 intermediate susceptible isolates (Fig 4, C). 261




Fig 4. The outcome of Carbapenem-resistant genes from the molecular detection 263 showing the presence of Carbapenem-resistant gene (A), distribution of bla OXA-48 264 and bla NDM-1 genes among CRE isolates (B), location of patients with CRE (C) and 265 the distribution of *bla OXA-48* and *NDM-1* genes (D). 266

267

262

Discussion 268

The knowledge of the distribution and surveillance of bacterial infections and their antibiotic 269 profiles are very critical for the creation of awareness, implementation of infection control 270 measures, and proper management of such infections. This is essential in developing 271 countries, especially in sub-Saharan Africa where studies have shown that many health 272 facilities have poor infection prevention and control (IPC) adherence. This challenge 273 translates into increased bacterial infections caused by multi-drug resistant bacteria and 274 275 subsequently resulted in increased morbidity and mortality [41, 42]. Resistance to β -lactam antimicrobials among Enterobacteriaceae has been caused largely by the acquisition of 276 resistant genes that encodes for β -lactamase enzymes [43, 44]. 277

From this study, the frequent isolates from clinical specimens were *Escherichia coli* (40.9%), 278 Citrobacter spp (32.6%), and Klebsiella pneumoniae (9.1%). This finding agrees with the 279 report by Blomberg and colleagues from a study conducted in Tanzania, which indicated that 280 Escherichia coli, Klebsiella oxvtoca, and Klebsiella pneumoniae are common bacteria 281 isolated from clinical samples of patients [45]. The findings of this study are consistent with a 282 finding in Ghana which reported Klebsiella pneumoniae, Enterobacter spp., and Escherichia 283 coli as the most isolated pathogenic Enterobacteriaceae from clinical specimens [46]. Again, 284 the results of the isolated organisms conform to the findings from a study conducted by Feglo 285 286 and colleagues in Ghana which reported that the most isolated Enterobacteriaceae from clinical specimens were predominantly E. coli, Klebsiella pneumoniae, and Klebsiella 287 oxytoca [47]. These commonly isolated bacteria have developed resistance to commonly used 288 antibiotics thereby making it difficult to effectively treat infections caused by such bacteria 289 290 [45].

Findings from this study have shown that *Citrobacter* spp (32.6%) is one of the common emerging uropathogens of urinary tract infections. Out of the 75 isolates of *Citrobacter* spp collected, 58(35.8%) of the total number of *Citrobacter* spp. were isolated from urine specimens. This agrees with the study conducted by Sami and colleagues which reported a prevalence of 3.5% *Citrobacter* spp [48], although this prevalence is lower than that of this study. The increase in the proportion of the *Citrobacter* spp. isolated could be attributed to the difference in geographical location.

The Enterobacteriaceae were predominantly isolated from females and mostly from urine specimens. The finding from this study is contrary to the study conducted by Nordmann and colleagues which indicated that there is no preference for sex by Enterobacteriaceae [49]. Their finding indicated that both genders are equally infected when the opportunity is created since these organisms are mainly opportunistic. Though the results from this study indicate

that both sexes are affected, more females (166, 72.2%) were affected. The rate of antimicrobial drug resistance is increasing rapidly, and the majority of commonly used drugs are significantly becoming ineffective for antimicrobial therapy [49, 50]. Antimicrobial resistance (AMR) is a threat to the effective prevention and treatment of infectious diseases caused by infectious pathogens [1]. Across the globe, antibiotics are the mainstay in the effective control and management of bacterial infections in the clinical setting [21].

The susceptibility profile of Enterobacteriaceae isolates in this study showed a low multidrug 309 resistance (32.5%) as compared to 89.5% in a similar study [4]. This study has shown a 310 relatively low resistance toward ampicillin (74.4%), cefuroxime (58.3%), and cefotaxime 311 (54.8%) as compared to the report by Agyepong and colleagues which indicated a high 312 resistance of Gram-negative bacteria towards, ampicillin (94.4%), cefuroxime (79.0%) and 313 cefotaxime (71.3%) [4]. Similarly, the results from this study were contrary to the report in 314 315 Ghana by Feglo and colleagues which reported isolates resistant to ampicillin (91.7%) and cefuroxime (70.6%) [47]. Resistance of isolates towards cefotaxime (54.8%) was high in this 316 317 study as compared to 48.1% as reported by Feglo and colleagues [47]. Results from the present study also support the findings by Labi and colleagues which indicated high antibiotic 318 resistance among members of the Enterobacteriaceae at the Korle Bu Teaching Hospital to 319 the combination of ampicillin/ gentamicin and ampicillin/ cefotaxime [51]. The resistance 320 among *Enterobacteriaceae* to ampicillin and other commonly used antibiotics is consistent 321 with other studies in sub-Saharan African countries such as Nigeria [52], Rwanda [53], 322 Ethiopia [54], Zimbabwe [55], and Tanzania [56]. The trend of antibiotic resistance rates in 323 the sub-region could be due to high antibiotic selection pressure which comes as a result of 324 the unregulated availability of antibiotics over the counter and cheap substandard antibiotics 325 influx in the sub-Saharan region [14, 57–59]. 326

ESBL production by Gram-negative bacteria poses a great challenge in the management of 327 Gram-negative bacterial infections. ESBL production may be associated with MDR. From 328 the study, the prevalence of ESBL producers among Enterobacteriaceae was 49.1% 329 (113/230) with the most ESBL-producing organism being E. coli (57.5%). The prevalence 330 (49.1%) of the ESBL was lower than that reported by Feglo and colleagues in a study 331 conducted in Ghana which reported a prevalence of 57.8% [47]. Furthermore, findings from 332 this study showed that ESBL prevalence was higher than the ESBL prevalence (37.96 %) 333 reported by Oduro-Mensah and colleagues in Ghana [60]. The difference in the prevalence 334 335 could be attributed to the difference in geographical location, sample size, and the period of sampling. Also, the result on the ESBL producers indicated that the ESBL harbouring isolates 336 were predominantly from outpatients (76.1%). This is not expected since inpatients are most 337 likely to have nosocomial infections and have been exposed to more antibiotics so are likely 338 339 to harbour ESBL producers. Inpatients are more at risk than outpatients. The ESBL distribution among outpatients and in-patients is contrary to the report by Khanfar and 340 colleagues from Saudi Arabia which reported ESBL producers to be higher in inpatients 341 (15.4%) than out-patients (4.5%) [61]. In like manner, a study conducted by Ouedraogo and 342 colleagues in Burkina Faso in the sub-Saharan region also reported ESBL prevalence to be 343 higher in hospitalized patients [62]. The high prevalence of ESBL producers among 344 outpatients could be due to the possible self-medication due to the unregulated availability of 345 346 antibiotics over the counter which may have escalated the transmission of the plasmidencoded genes within the community. The community may serve as a reservoir for ESBL 347 which may eventually result in a possible outbreak of ESBL-carrying strains of 348 349 Enterobacteriaceae if not contained.

The outcome of the detection of the carbapenem-resistant gene via PCR showed the presence of *bla NDM-1* and *bla OXA-48* among different bacteria. In addition, the urine specimens

exhibited more carbapenem-resistant genes than the other specimens. Also in this study, the 352 most implicated bacteria were Proteus spp, Citrobacter spp, and E. coli. This result is in 353 agreement with the report by Codjoe and colleagues [37] and Quansah and colleagues [36] 354 which indicated the presence of both *bla NDM-1* and *bla OXA-48* in Ghana. Furthermore, the 355 CRE-resistant isolates which harboured carbapenem-resistant genes were also ESBL-356 producing bacteria using the phenotypic method of detection. This agrees with the study 357 358 conducted by Bornet and colleagues [63] which affirms that most CREs are ESBL producers. Reports from this study agree with surveillance studies in the western world and developed 359 360 countries, which indicated that there had been reports of several rates of carbapenemase producers globally. In Europe, Germany had a prevalence of CRE of less than 1 [64]. When 361 compared with prevalence in these developed countries, the prevalence from this study was 362 high. This could be due to the well-regulated use of drugs (antibiotics) in developed countries 363 compared to developing countries. For instance in Asia, China had a reported prevalence of 364 33.3% which was mainly due to NDM-1-producing CRE [65]. This prevalence in China is 365 high when compared to the prevalence of CRE in this study. The possible importation of 366 resistance genes has been found in a few countries such as South Africa due to tourism and 367 migration [66]. 368

369 Conclusion

The study has demonstrated the high prevalence of carbapenem-resistant and high ESBL production among *Enterobacteriaceae*. ESBL production was found among 49.1% of isolates and the prevalence of MDR and CRE were 35.2% and 5.7% respectively. *E. coli*, *Citrobacter* spp., *K. pneumoniae*, and *Klebsiella oxytoca* were the most common causative organisms isolated. The study found high rates of MDR among *E. coli* and *Citrobacter* spp. The *Enterobacteriaceae* were most sensitive towards amikacin, imipenem, and meropenem and most resistant towards ampicillin, cefuroxime, and cefotaxime. These results should

377	guide the empirical treatment of bacterial infections caused by Enterobacteriaceae in Cape
378	Coast Teaching Hospital of Ghana. Other recommendations may include PCR to determine
379	the types of ESBL in CCTH and adopting strict infection control measures to prevent the
380	rapid spread of resistance.
381	
382	Acknowledgment
383	We would like to thank the Cape Coast Teaching Hospital staff, especially the technical staff
384	at the bacteriology unit of the laboratory department.
385	Funding
386	This study was funded by the first author.
387	Availability of data and materials
388	Data and materials have been provided in the main manuscript. Additional information can be
389	provided by the corresponding author upon request.
390	Authors' contributions
391	The study was conceptualized and jointly designed by JS and AOO. AOO supervised the
392	work. JS and IOF collected the data and undertook laboratory analysis. Data analysis was
393	done with assistance from FTA. JS, IOF, and FTA prepared the manuscript with the
394	assistance of AOO. All authors read and approved the final manuscript.
395	Conflicts of Interest: The authors declare that they have no conflict of interest.
396	References
397	1. World Health Organization. Antimicrobial resistance:: Global report on surveillance;
398	2014.

- World Health Organization 2018 Global Antimicrobial Resistance Surveillance System
 (GLASS) Report Early Implementation 2017–2018 2018.
- 3. Singh N, Manchanda V. Control of multidrug-resistant Gram-negative bacteria in lowand middle-income countries-high impact interventions without much resources. Clin
 Microbiol Infect. 2017;23:216–8. doi:10.1016/j.cmi.2017.02.034.
- 404 4. Agyepong N, Govinden U, Owusu-Ofori A, Essack SY. Multidrug-resistant gram405 negative bacterial infections in a teaching hospital in Ghana. Antimicrob Resist Infect
 406 Control. 2018;7:37. doi:10.1186/s13756-018-0324-2.
- 407 5. Méndez-Vilas A. Microbial pathogens and strategies for combating them: Science,
 408 technology and education 2013;4. Badajoz: Formatex Research Center.
- 6. Rossolini GM, Mantengoli E, Docquier J-D, Musmanno RA, Coratza G. Epidemiology
 of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant
 strains. J Nat Sci. 2007;30:332–9.
- 7. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing
 Enterobacteriaceae. Emerging Infectious Diseases. 2011;17:1791–8.
 doi:10.3201/eid1710.110655.
- 8. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. American
 Journal of Infection Control. 2006;34:S20-8; discussion S64-73.
 doi:10.1016/j.ajic.2006.05.238.
- 9. Bitew A, Tsige E. High Prevalence of Multidrug-Resistant and Extended-Spectrum βLactamase-Producing Enterobacteriaceae: A Cross-Sectional Study at Arsho Advanced
 Medical Laboratory, Addis Ababa, Ethiopia. Journal of Tropical Medicine.
 2020;2020:6167234. doi:10.1155/2020/6167234.
- 422 10. Shilpakar A, Ansari M, Rai KR, Rai G, Rai SK. Prevalence of multidrug-resistant and
 423 extended-spectrum beta-lactamase producing Gram-negative isolates from clinical

424 samples in a tertiary care hospital of Nepal. Trop Med Health. 2021;49:23.
425 doi:10.1186/s41182-021-00313-3.

- 11. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization,
 epidemiology, and detection of this important resistance threat. Clin Microbiol Rev.
 2001;14:933-51, table of contents. doi:10.1128/CMR.14.4.933-951.2001.
- 12. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JDD, Quentin C, Calbo ES, et al. A
 multinational survey of risk factors for infection with extended-spectrum beta-lactamaseproducing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682–
 90. doi:10.1086/604713.
- 433 13. Perez F, van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most
 434 vulnerable patients. Cleveland Clinic Journal of Medicine. 2013;80:225–33.
 435 doi:10.3949/ccjm.80a.12182.
- 436 14. Mushi MF, Mshana SE, Imirzalioglu C, Bwanga F. Carbapenemase genes among
 437 multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza,
 438 Tanzania. BioMed Research International. 2014;2014:303104. doi:10.1155/2014/303104.
- 15. Tada T, Miyoshi-Akiyama T, Dahal RK, Mishra SK, Ohara H, Shimada K, et al.
 Dissemination of multidrug-resistant Klebsiella pneumoniae clinical isolates with various
 combinations of carbapenemases (NDM-1 and OXA-72) and 16S rRNA methylases
 (ArmA, RmtC and RmtF) in Nepal. International Journal of Antimicrobial Agents.
 2013;42:372–4. doi:10.1016/j.ijantimicag.2013.06.014.
- 16. Leski TA, Taitt CR, Bangura U, Stockelman MG, Ansumana R, Cooper WH, et al. High
 prevalence of multidrug resistant Enterobacteriaceae isolated from outpatient urine
 samples but not the hospital environment in Bo, Sierra Leone. BMC Infectious Diseases.
 2016;16:167. doi:10.1186/s12879-016-1495-1.

- 17. Leski T, Vora GJ, Taitt CR. Multidrug resistance determinants from NDM-1-producing
 Klebsiella pneumoniae in the USA. International Journal of Antimicrobial Agents.
 2012;40:282–4. doi:10.1016/j.ijantimicag.2012.05.019.
- 451 18. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past,
 452 present, and future. Antimicrobial Agents and Chemotherapy. 2011;55:4943–60.
 453 doi:10.1128/AAC.00296-11.
- 454 19. Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems
 455 to patients with IgE-mediated allergy to penicillins or cephalosporins? Clin Infect Dis.
 456 2014;59:1113–22. doi:10.1093/cid/ciu587.
- 457 20. Wilson H, Török ME. Extended-spectrum β-lactamase-producing and carbapenemase458 producing Enterobacteriaceae. Microbial Genomics 2018. doi:10.1099/mgen.0.000197.
- 459 21. Torok ME, Moran E, Cooke FJ. Oxford Handbook of Infectious Diseases and
 460 Microbiology. In: Oxford handbook of infectious diseases and microbiology. 2nd ed.
 461 [Oxford]: Oxford University Press; 2016.
- 462 22. P. Oduro. Prevalence of Carbapenemase Producing Enterobacteriaceae in Urinary Tract
 463 Infection Patients in Ghana. undefined. 2016.
- 464 23. Ssekatawa K, Byarugaba DK, Wampande E, Ejobi F. A systematic review: the current
 465 status of carbapenem resistance in East Africa. BMC Res Notes. 2018;11:629.
 466 doi:10.1186/s13104-018-3738-2.
- 467 24. Moyo SJ, Aboud S, Kasubi M, Lyamuya EF, Maselle SY. Antimicrobial resistance
 468 among producers and non-producers of extended spectrum beta-lactamases in urinary
 469 isolates at a tertiary Hospital in Tanzania. BMC Research Notes. 2010;3:348.
 470 doi:10.1186/1756-0500-3-348.

- 471 25. Warnes SL, Highmore CJ, Keevil CW. Horizontal transfer of antibiotic resistance genes
 472 on abiotic touch surfaces: implications for public health. Am Soc Microbiol. 2012;3:6–
 473 12. Am Soc Microbiol. 2012;3:6.
- 474 26. Moyo S, Haldorsen B, Aboud S, Blomberg B, Maselle SY, Sundsfjord A, et al.
- 475 Identification of VIM-2-producing Pseudomonas aeruginosa from Tanzania is associated
- with sequence types 244 and 640 and the location of blaVIM-2 in a TniC integron.
- 477 Antimicrobial Agents and Chemotherapy. 2015;59:682–5. doi:10.1128/AAC.01436-13.
- 478 27. Poirel L, Revathi G, Bernabeu S, Nordmann P. Detection of NDM-1-producing
 479 Klebsiella pneumoniae in Kenya. Antimicrobial Agents and Chemotherapy.
 480 2011;55:934–6. doi:10.1128/AAC.01247-10.
- 28. Revathi G, Siu LK, Lu P-L, Huang L-Y. First report of NDM-1-producing Acinetobacter
 baumannii in East Africa. Int J Infect Dis. 2013;17:e1255-8.
 doi:10.1016/j.ijid.2013.07.016.
- 29. Perovic O, Ismail H, Quan V, Bamford C, Nana T, Chibabhai V, et al. Carbapenemresistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South
 Africa, 2015 to 2018. European Journal of Clinical Microbiology & Infectious Diseases.
 2020;39:1287–94. doi:10.1007/s10096-020-03845-4.
- 30. Adesanya OA, Igwe HA. Carbapenem-resistant Enterobacteriaceae (CRE) and gramnegative bacterial infections in south-west Nigeria: a retrospective epidemiological
 surveillance study. AIMS Public Health. 2020;7:804–15.
 doi:10.3934/publichealth.2020062.
- 492 31. Vasaikar SD, Hanise P, Abaver DT. Epidemiology, risk factors and molecular analysis of
 493 carbapenem-resistant Enterobacteriaceae (CRE) in Mthatha, Eastern Cape, South Africa.
 494 International Journal of Infectious Diseases. 2020;101:54. doi:10.1016/j.ijid.2020.09.173.

32. Thomas TSM, Duse AG. Epidemiology of carbapenem-resistant Enterobacteriaceae 495 (CRE) and comparison of the phenotypic versus genotypic screening tests for the 496 detection of carbapenemases at a tertiary level, academic hospital in Johannesburg, South 497 Africa. Southern African Journal of Infectious Diseases. 2018:1-7. 498 doi:10.1080/23120053.2018.1509184. 499

- 33. Adrian Brink, Jennifer Coetzee, Cornelis Clay, Craig Corcoran, Johan van Greune, J D
 Deetlefs, et al. The spread of carbapenem-resistant Enterobacteriaceae in South Africa:
 Risk factors for acquisition and prevention. South African Medical Journal.
 2012;102:599–601.
- 34. Ngbede EO, Adekanmbi F, Poudel A, Kalalah A, Kelly P, Yang Y, et al. Concurrent
 Resistance to Carbapenem and Colistin Among Enterobacteriaceae Recovered From
 Human and Animal Sources in Nigeria Is Associated With Multiple Genetic
 Mechanisms. Front. Microbiol. 2021;12:740348. doi:10.3389/fmicb.2021.740348.
- 508 35. El Wartiti MA, Bahmani F-Z, Elouennass M, Benouda A. Prevalence of carbapenemaseproducing enterobacteriaceae in a University Hospital in Rabat, Morocco: A 19-months
 prospective study. International Arabic Journal of Antimicrobial Agents. 2012;2:1–6.
 doi:10.3823/718.
- 36. Quansah E, Amoah Barnie P, Omane Acheampong D, Obiri-Yeboah D, Odarkor Mills R,
 Asmah E, et al. Geographical Distribution of β-Lactam Resistance among Klebsiella spp.
 from Selected Health Facilities in Ghana. Tropical Medicine and Infectious Disease
 2019. doi:10.3390/tropicalmed4030117.
- 516 37. Codjoe FS, Donkor ES, Smith TJ, Miller K. Phenotypic and Genotypic Characterization
- of Carbapenem-Resistant Gram-Negative Bacilli Pathogens from Hospitals in Ghana.
- 518 Microbial Drug Resistance. 2019;25:1449–57. doi:10.1089/mdr.2018.0278.

- 519 38. Cape Coast Teaching Hospital. Cape Coast Teaching Hospital:: 2018 Performance
 520 Report. Cape Coast; 2018.
- 39. Ghana Statistical Service. 2010 Population & Housing Census:: District analytical report.
 Cape Coast Municipality. Accra; 2010.
- 40. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. Wayne,
 PA; 2018.
- 41. Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al. Antimicrobial
 resistance: a global view from the 2013 World Healthcare-Associated Infections Forum.
- 527 Antimicrob Resist Infect Control. 2013;2:31. doi:10.1186/2047-2994-2-31.
- 42. Samuel S, Kayode O, Musa O, Nwigwe G, Aboderin A, Salami T, Taiwo S. Nosocomial
 infections and the challenges of control in developing countries. Afr J Clin Exp
 Microbiol. 2010;11:102–9.
- 43. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended
 spectrum beta-lactamases: Types, epidemiology and treatment. Saudi Journal of
 Biological Sciences. 2015;22:90–101. doi:10.1016/j.sjbs.2014.08.002.
- 44. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med. 2005;352:380–
 91. doi:10.1056/NEJMra041359.
- 45. Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DSM, Urassa WK, et al. High
 rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with
 extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. Journal of Clinical
 Microbiology. 2005;43:745–9. doi:10.1128/JCM.43.2.745-749.2005.
- 540 46. Codjoe FS. Detection and characterisation of carbapenem-resistant gram-negative bacilli541 infections in Ghana.
- 542 47. Feglo PK, Gbedema SY, Quay SNA, Adu-Sarkodie Y, Opoku-Okrah C. Occurrence,
 543 species distribution and antibiotic resistance of Proteus isolates: A case study at the

Komfo Anokye Teaching Hospital (KATH) in Ghana. International Journal of PharmaSciences and Research. 2010;1.

- 48. Sami H, Sultan A, Rizvi M, Khan F, Ahmad S, Shukla I, Khan H. Citrobacter as a
 uropathogen, its prevalence and antibiotics susceptibility pattern. CHRISMED J Health
 Res. 2017;4:23. doi:10.4103/2348-3334.196037.
- 49. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae
 carbapenemase-producing bacteria. The Lancet Infectious Diseases. 2009;9:228–36.
 doi:10.1016/S1473-3099(09)70054-4.
- 552 50. Donkor ES, Dayie NT, Badoe EV. Vaccination against pneumococcus in West Africa:
 553 perspectives and prospects. Int J Gen Med. 2013;6:757–64. doi:10.2147/IJGM.S45842.
- 554 51. Labi A-K, Obeng-Nkrumah N, Bjerrum S, Enweronu-Laryea C, Newman MJ. Neonatal
 bloodstream infections in a Ghanaian Tertiary Hospital: Are the current antibiotic
 recommendations adequate? BMC Infect Dis. 2016;16:598. doi:10.1186/s12879-0161913-4.
- 52. Ogbolu DO, Daini OA, Ogunledun A, Alli AO, Webber MA. High levels of multidrug
 resistance in clinical isolates of Gram-negative pathogens from Nigeria. International
 Journal of Antimicrobial Agents. 2011;37:62–6. doi:10.1016/j.ijantimicag.2010.08.019.
- 53. Carroll M, Rangaiahagari A, Musabeyezu E, Singer D, Ogbuagu O. Five-Year
 Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary HealthCare Facility in Kigali, Rwanda. The American Journal of Tropical Medicine and
 Hygiene. 2016;95:1277–83. doi:10.4269/ajtmh.16-0392.
- 54. Muluye D, Wondimeneh Y, Ferede G, Nega T, Adane K, Biadgo B, et al. Bacterial
 isolates and their antibiotic susceptibility patterns among patients with pus and/or wound
 discharge at Gondar university hospital. BMC Research Notes. 2014;7:619.
 doi:10.1186/1756-0500-7-619.

- 55. Mbanga J, Dube S, Munyanduki H. Prevalence and drug resistance in bacteria of the
 urinary tract infections in Bulawayo province, Zimbabwe. East Afr J Public Health.
 2010;7:229–32.
- 572 56. Kumburu HH, Sonda T, Mmbaga BT, Alifrangis M, Lund O, Kibiki G, Aarestrup FM.
- 573 Patterns of infections, aetiological agents and antimicrobial resistance at a tertiary care
- hospital in northern Tanzania. Tropical Medicine and International Health. 2017;22:454–

575 64. doi:10.1111/tmi.12836.

- 576 57. Mshana SE, Matee M, Rweyemamu M. Antimicrobial resistance in human and animal
 pathogens in Zambia, Democratic Republic of Congo, Mozambique and Tanzania: an
 urgent need of a sustainable surveillance system. Annals of Clinical Microbiology and
 Antimicrobials. 2013;12:28. doi:10.1186/1476-0711-12-28.
- 580 58. Ocan M, Bwanga F, Bbosa GS, Bagenda D, Waako P, Ogwal-Okeng J, Obua C. Patterns
 and predictors of self-medication in northern Uganda. PLoS ONE. 2014;9:e92323.
 doi:10.1371/journal.pone.0092323.
- 59. Donkor ES, Tetteh-Quarcoo PB, Nartey P, Agyeman IO. Self-medication practices with
 antibiotics among tertiary level students in Accra, Ghana: a cross-sectional study.
 International Journal of Environmental Research and Public Health. 2012;9:3519–29.
 doi:10.3390/ijerph9103519.
- 60. Oduro-Mensah D, Obeng-Nkrumah N, Bonney EY, Oduro-Mensah E, Twum-Danso K,
 Osei YD, Sackey ST. Genetic characterization of TEM-type ESBL-associated
 antibacterial resistance in Enterobacteriaceae in a tertiary hospital in Ghana. Annals of
 Clinical Microbiology and Antimicrobials. 2016;15:29. doi:10.1186/s12941-016-0144-2.
- 591 61. Khanfar HS, Bindayna KM, Senok AC, Botta GA. Extended spectrum beta-lactamases
 592 (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and
 593 community settings. J Infect Dev Ctries. 2009;3:295–9. doi:10.3855/jidc.127.

- 62. Ouedraogo A-S, Sanou M, Kissou A, Sanou S, Solaré H, Kaboré F, et al. High 594 prevalence of extended-spectrum *B*-lactamase producing enterobacteriaceae among 595 Burkina Faso. BMC Infectious 596 clinical isolates in Diseases. 2016:16:326. doi:10.1186/s12879-016-1655-3. 597
- 63. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes.
 Antimicrobial Agents and Chemotherapy. 2004;48:1–14. doi:10.1128/AAC.48.1.114.2004.
- 601 64. Ehrhard I, Karaalp A-K, Hackel T, Höll G, Rodewald N, Reif U, et al.
 602 Prävalenzerhebung zum Vorkommen von Carbapenemase-Bildnern in sächsischen
 603 Kliniken. [Prevalence of carbapenemase-producing bacteria in hospitals in Saxony,
 604 Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.
 605 2014;57:406–13. doi:10.1007/s00103-013-1914-z.
- 606 65. Qin S, Fu Y, Zhang Q, Qi H, Wen JG, Xu H, et al. High incidence and endemic spread of
 607 NDM-1-positive Enterobacteriaceae in Henan Province, China. Antimicrobial Agents
 608 and Chemotherapy. 2014;58:4275–82. doi:10.1128/AAC.02813-13.

609 66. Brink A, Coetzee J, Clay C, Corcoran C, van Greune J, Deetlefs JD, et al. The spread of
610 carbapenem-resistant Enterobacteriaceae in South Africa: Risk factors for acquisition and
611 prevention. South African Medical Journal. 2012;102:599–601.

612